| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 05/10/2005 | US6890958 Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
| 05/10/2005 | US6890947 (S)-3-(1-(2-(2-chloro-phenyl)-5-methyl-oxazol-4-ylmethyl)-1H -indol-5-yl)-2-ethoxy-propionic acid; peroxisome proliferator activated receptors (PPARs) |
| 05/10/2005 | US6890945 Administering a imidazo(4,5,1-ij)quinoline compound |
| 05/10/2005 | US6890943 3-acylated pyridoxal derivatives used to treat vitamin B6 deficiency, cardiovascular diseases, melanoma and other related diseases |
| 05/10/2005 | US6890938 Antiinflammatory agents |
| 05/10/2005 | US6890937 Inhibiting the activity of one or more of MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibitory activity against MMP-1 |
| 05/10/2005 | US6890928 Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
| 05/10/2005 | US6890927 Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| 05/10/2005 | US6890925 Treating insulin resistance, hypertension, angina, ischemia, renal disease or Raynaud's disease, by administering pyrazole derivatives such as 1-(p-(morpholinocarbonylamino)phenyl)-3,5-di(trifluoromethyl)pyrazole |
| 05/10/2005 | US6890922 For treatment of erectile dysfunction as well as female sexual dysfunction, incontinence, and hypertrophy of the prostate; inhibitors of cGMP-metabolizing phosphodiesterases (cGMP= cyclic guanosine monophosphate) |
| 05/10/2005 | US6890918 Pharmaceutical compositions including ACE/NEP inhibitors and bioavailability enhancers |
| 05/10/2005 | US6890915 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| 05/10/2005 | US6890914 Method of locking 1α-OH of vitamin D compounds in axial orientation |
| 05/10/2005 | US6890906 Administering a compound which binds to a galectin |
| 05/10/2005 | US6890751 NRG-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 05/10/2005 | US6890546 Stents, catheters, arterio-venous grafts, by-pass grafts and drug delivery ballons with surface coating containing a rapamycin derivative having a tetrazole group |
| 05/10/2005 | US6890529 Edible foods, functional products or pharmaceuticals; nutraceutical; beverages |
| 05/10/2005 | CA2250569C Novel phenanthridines substituted in the 6 position |
| 05/06/2005 | WO2005040148A1 New rar$g(b) receptor-activating ligand, method for the preparation thereof and use thereof in human medicine and in cosmetics |
| 05/06/2005 | WO2005039638A2 Therapeutic agent for heart failure comprising an angiotensin ii receptor antagonist and a matrix metalloproteinase inhibitor |
| 05/06/2005 | WO2005039625A1 Growth hormone secretagogue receptor agonists |
| 05/06/2005 | WO2005039621A1 Fibroblast-mobilizing agent containing g-csf and wound remedy |
| 05/06/2005 | WO2005039602A1 Pharmacologically functional water and use thereof |
| 05/06/2005 | WO2005039599A1 Matrix metalloprotease inhibitor containing polylactic acid mixture |
| 05/06/2005 | WO2005039582A1 METHODS OF TREATING ATHEROSCLEROSIS USING NF-kB INHIBITORS |
| 05/06/2005 | WO2005039559A1 Composition functioning to prevent or mitigate symptom or disease attributable to blood vessel aging |
| 05/06/2005 | WO2005039541A1 Coenzyme q10 enclosing capsule |
| 05/06/2005 | WO2005027895A3 Thyroid hormone analogs and methods of use in angiogenesis |
| 05/06/2005 | WO2005021541A3 Process for the production of polymorphs of rosiglitazone maleate |
| 05/06/2005 | WO2005007239B1 Use of dapsone as a neuroprotector in cerebral infarction |
| 05/06/2005 | WO2004112839A3 Specific high-relaxivity conjugate compounds for magnetic resonance imaging |
| 05/06/2005 | WO2004087132A8 Combination drug therapy for treating hypertension |
| 05/06/2005 | WO2004071529A3 Uses of anti-insulin-like growth factor i receptor antibodies |
| 05/06/2005 | WO2004015096A8 Leech extracts for stents |
| 05/06/2005 | WO2003068746A8 Aryl ureas as kinase inhibitors |
| 05/06/2005 | WO2003010286A3 Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 05/06/2005 | WO2002095007A3 Conjugates activated by cell surface proteases and therapeutic uses thereof |
| 05/06/2005 | CA2842308A1 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
| 05/06/2005 | CA2543817A1 Fibroblast-mobilization agent containing a g-csf for repair of myocardial infarct lesion |
| 05/06/2005 | CA2543630A1 Use of cyclic anabaenopeptin-type peptides for the treatment of a condition wherein inhibition of carboxypeptidase u is beneficial, novel anabaenopeptin derivatives and intermediates thereof |
| 05/06/2005 | CA2543404A1 Novel inhibitor of the formation of advanced glycation end product and aldose reductase inhibitor |
| 05/06/2005 | CA2540543A1 Tetrahydropyridine derivatives |
| 05/06/2005 | CA2539726A1 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase |
| 05/06/2005 | CA2539193A1 New rarbeta receptor-activating ligand, method for the preparation ther eof and use thereof in human medicine and in cosmetics |
| 05/06/2005 | CA2537224A1 Heterocycle-substituted pteridine derivatives and their use in therapy |
| 05/05/2005 | US20050096469 Mono-ester and asymmetrically substatuted di-ester pro-drugs of dopamide d1 receptor agonists |
| 05/05/2005 | US20050096468 Inhibitors of histone deacetylase |
| 05/05/2005 | US20050096397 Adding trifluoroacetic acid dropwise to a solution of dimethylphenylsilane and (S)-amino-1-(2,5-dimethoxy-phenyl)-1-propanone, the amino group of which is protected, for example, with a methoxycarbonyl group; reduction; deprotecting; salt formation |
| 05/05/2005 | US20050096388 Compositions and methods for treating or preventing diseases of body passageways |
| 05/05/2005 | US20050096382 Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof |
| 05/05/2005 | US20050096378 Fundic relaxation; dyspepsia, early satiety, bloating and anorexia; 1-[3-[[(3,4-dihydro-2H-1-benzopyran-2-yl- )methyl]amino]-2-hydroxypropyl]-2,4-imidazolidinedione |
| 05/05/2005 | US20050096377 Substituted sulfonamide-indoles |
| 05/05/2005 | US20050096363 Activator of peroxisome proliferator-activated receptor delta |
| 05/05/2005 | US20050096356 2-[[6-Methoxy-3-pyridinyl]methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide hydrochloride salt or its tautomer; treating retinopathy or age-related macula degeneration |
| 05/05/2005 | US20050096331 Alkyl carboxylic acids and their derivatives; antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds; better efficacy, potency and lower toxicity |
| 05/05/2005 | US20050096326 4-(4-methylpiperazin-1-yl)4V-(4-morpholinophenyl)-indan-2-carboxamide; h5-HT1B receptor antagonist; serotonin-mediated disorders; oral bioavailability |
| 05/05/2005 | US20050096321 affinity for peripheral-type benzodiazepine receptors; in vitro and in vivo affinity; chemical intermediates |
| 05/05/2005 | US20050096320 potent inhibitors of cyclic guanosine 3',5'-monophosphate-metabolizing phosphodiesterases (cGMP-PDEs)/phosphodiesterase isoenzymes PDE-I, PDE-II, PDE-V; therapeutic, antiaggregatory, antithrombotic, antiproliferative, antivasospastic, vasodilatory, natriuretic and diuretic effects; erectile dysfunction |
| 05/05/2005 | US20050096313 Substance P; 2-(phenyl)-4-(3-oxo-piperazin-1-yl-)-piperidine-1-carboxylic acid; benzyl-methylamide; antagonists of the NK1 receptor; antidepressant, antiolytic; antiemetic |
| 05/05/2005 | US20050096312 Antiserotonine agents; antidepressants; eating disorders; anxiolytic agents; sleep disorders; gastrointestinal disorders; cardiovascular disorders; muscular disorders; endocrine system diseases; muscular disorders; psychological disorders |
| 05/05/2005 | US20050096293 Analogs of nitrobenzylthioinosine |
| 05/05/2005 | US20050096290 Treatment of diseases with aptamers with inverted nucleotide capped ends for treatment of neovascularization related diseases like age related macular degeneration |
| 05/05/2005 | US20050096286 Plasmid encoding of fibroblast growth factor as treatment for hypercholesterolemia or diabetes |
| 05/05/2005 | US20050096279 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 05/05/2005 | US20050096277 Methods of prevention and treatment using apolipoprotein analogues |
| 05/05/2005 | US20050096276 Hibernating myocardium can't contract like healthy muscles detection of norepinephrine can predict health of heart muscles |
| 05/05/2005 | US20050096268 Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
| 05/05/2005 | US20050096267 Fusion protein contains amino acid sequence with 9 to 13 residues of arginine; antagonist of Nuclear Factor Activated T cell (NFAT); short effectiveness and no side effects or antigenicity; signal sequence, immunosuppressants, biodrugs |
| 05/05/2005 | US20050096256 Compositions for manipulating the lifespan and stress response of cells and organisms |
| 05/05/2005 | US20050096253 Utilization of inhibitors of rho-kinases for stimulating nerve growth, inhibiting scar tissue formation and/or reducing a secondary lesion |
| 05/05/2005 | US20050096064 Access parameter adaptation and packet data resource management using detailed mobile status information |
| 05/05/2005 | US20050095297 Nanoparticulate formulations of fenofibrate |
| 05/05/2005 | US20050095238 Treating a disease associated with leukocyte infiltration of mucosal tissues, such as inflammatory bowel disease, asthma, graft vs host disease, pancreatitis, diabetes, or sinutitis with a humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for alpha 4 beta 7 integrin |
| 05/05/2005 | US20050095224 Compositions and method for treating hepatitis virus infection |
| 05/04/2005 | EP1528061A1 Heterocyclic derivatives which inhibit factor Xa |
| 05/04/2005 | EP1528058A1 Polymorphic crystalline forms of celecoxib |
| 05/04/2005 | EP1527779A1 Sustained release ranolazine formulations |
| 05/04/2005 | EP1527777A1 Composition with antioxidant properties comprising an ester of ascorbic acid and a benzoyl rest |
| 05/04/2005 | EP1527171A2 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 05/04/2005 | EP1527169A2 Leech extracts for stents |
| 05/04/2005 | EP1527159A1 Probiotic propionibacterium jensenii 702 |
| 05/04/2005 | EP1527084A2 Promoters exhibiting endothelial cell specificity and methods of using same |
| 05/04/2005 | EP1527076A1 Dihydro-dibenzo (b,e) oxepine based selective estrogen receptor modulators, compositions and methods |
| 05/04/2005 | EP1527074A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 05/04/2005 | EP1527070A1 Azole methylidene cyanide derivatives and their use as protein kinase modulators |
| 05/04/2005 | EP1527068A2 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 05/04/2005 | EP1527063A1 The 9, 11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma |
| 05/04/2005 | EP1527051A1 Pyrimidyl sulphone amide derivatives as chemokine receptor modulators |
| 05/04/2005 | EP1527046A1 Indoline derivatives substituted in position 6, production and use thereof as medicaments |
| 05/04/2005 | EP1526895A2 Methods for treating carbonic anhydrase mediated disorders |
| 05/04/2005 | EP1526869A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 05/04/2005 | EP1526867A2 Use of erythropoietin |
| 05/04/2005 | EP1526862A1 Simmondsin for use as an angiogenesis inhibitor |
| 05/04/2005 | EP1526860A2 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof |
| 05/04/2005 | EP1526852A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 05/04/2005 | EP1526847A2 Pharmaceutical dosage form comprising a sulfite compound |
| 05/04/2005 | EP1526846A2 Gelatin capsule exhibiting reduced cross-linking |
| 05/04/2005 | EP1526845A2 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 05/04/2005 | EP1526844A2 Pellicle-resistant gelatin capsule |
| 05/04/2005 | EP1448553B1 N-heterocyclyl hydrazides as neurotrophic agents |